Literature DB >> 12531948

Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study.

Y Zoukos1, T N Thomaides, D Kidd, M L Cuzner, A Thompson.   

Abstract

BACKGROUND: Beta(2) adrenoreceptor expression on peripheral blood mononuclear cells is increased in progressive multiple sclerosis. This increase has been correlated with disease activity in relapsing-remitting multiple sclerosis.
OBJECTIVE: To determine the beta(2) adrenoreceptor expression in primary and secondary progressive multiple sclerosis in relation to findings on magnetic resonance imaging (MRI) and clinical disease activity.
METHODS: 10 patients with multiple sclerosis were studied (five with primary progressive and five with secondary progressive forms of the disease) over a period of six months. Monthly clinical and MRI assessments of the brain and spinal cord were carried out. Beta(2) adrenoreceptor expression was assessed monthly using a ligand binding assay with [(125)I]iodocyanopindolol. Expression of beta(2) adrenoceptors on peripheral blood mononuclear cells was also assessed in five normal controls over a similar period.
RESULTS: The mean (SEM) value of beta(2) adrenoreceptor density for the five normal controls was 1346 (183) sites/cell, with affinity Kd of 120 (40) pM. MRI disease activity in primary progressive multiple sclerosis was reported on two occasions and on those occasions the expression of beta(2) adrenoreceptors was increased in excess of 1900 sites/cell; in the remaining 28 observations beta(2) adrenoreceptor expression was within the normal range (800 to 1900 sites/cell). In patients with secondary progressive disease, MRI disease activity was observed on 16 occasions. In these patients expression of beta(2) adrenoreceptors was increased in excess of 2000 sites/cell in all measurements except in one subject who did not show MRI activity throughout the six months period of study. The affinity of the receptors was within the normal range in all cases.
CONCLUSIONS: Increased expression of beta(2) adrenoreceptors was correlated with MRI disease activity in two patients with primary progressive multiple sclerosis. In secondary progressive multiple sclerosis, increased expression of beta(2) adrenoreceptors tended not to correlate with MRI disease activity. This may reflect a persistent Th1 immune reaction in the secondary progressive form of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531948      PMCID: PMC1738290          DOI: 10.1136/jnnp.74.2.197

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  40 in total

1.  Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis.

Authors:  Y Zoukos; D Kidd; M N Woodroofe; B E Kendall; A J Thompson; M L Cuzner
Journal:  Brain       Date:  1994-04       Impact factor: 13.501

2.  Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization.

Authors:  M N Woodroofe; M L Cuzner
Journal:  Cytokine       Date:  1993-11       Impact factor: 3.861

3.  Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function.

Authors:  M M Whalen; A D Bankhurst
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

4.  Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis.

Authors:  C Z Lu; M A Jensen; B G Arnason
Journal:  J Neuroimmunol       Date:  1993-07       Impact factor: 3.478

5.  High beta-adrenoceptor density on peripheral blood mononuclear cells in progressive multiple sclerosis: a manifestation of autonomic dysfunction?

Authors:  Y Zoukos; T Thomaides; C J Mathias; M L Cuzner
Journal:  Acta Neurol Scand       Date:  1994-12       Impact factor: 3.209

Review 6.  Immunological aspects of demyelinating diseases.

Authors:  R Martin; H F McFarland; D E McFarlin
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

7.  beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1.

Authors:  Y Zoukos; J P Leonard; T Thomaides; A J Thompson; M L Cuzner
Journal:  Ann Neurol       Date:  1992-06       Impact factor: 10.422

8.  Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis.

Authors:  D Kidd; J W Thorpe; A J Thompson; B E Kendall; I F Moseley; D G MacManus; W I McDonald; D H Miller
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

9.  Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity.

Authors:  P Rieckmann; M Albrecht; B Kitze; T Weber; H Tumani; A Broocks; W Lüer; A Helwig; S Poser
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

10.  Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors:  A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal:  Ann Neurol       Date:  1991-01       Impact factor: 10.422

View more
  7 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications.

Authors:  Mario Habek
Journal:  Clin Auton Res       Date:  2019-04-08       Impact factor: 4.435

Review 3.  Autonomic dysfunction, immune regulation, and multiple sclerosis.

Authors:  Juan Manuel Racosta; Kurt Kimpinski
Journal:  Clin Auton Res       Date:  2015-12-21       Impact factor: 4.435

Review 4.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

Review 5.  Impaired Neurovisceral Integration of Cardiovascular Modulation Contributes to Multiple Sclerosis Morbidities.

Authors:  Zohara Sternberg
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 6.  Genetic, Epigenetic, and Environmental Factors Influencing Neurovisceral Integration of Cardiovascular Modulation: Focus on Multiple Sclerosis.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2015-10-26       Impact factor: 3.843

Review 7.  Molecular mechanisms underlying β-adrenergic receptor-mediated cross-talk between sympathetic neurons and immune cells.

Authors:  Dianne Lorton; Denise L Bellinger
Journal:  Int J Mol Sci       Date:  2015-03-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.